BNP Paribas analyst Kirsty Ross-Stewart upgraded Swedish Orphan Biovitrum (BIOVF) to Outperform from Underperform with a SEK 475 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOVF:
- Sobi Posts Strong 2025 Growth and Expands Rare Disease Portfolio With Strategic Deals and Launches
- Swedish Orphan Biovitrum Ab (0MTD) Q4 Earnings Cheat Sheet
- Sobi Lifts 2025 Revenue and Profitability Above Previous Outlook
- Sobi Advances Gamifant After Positive Phase 2a Data in Interferon-Gamma–Driven Sepsis
- Sobi Acquires Arthrosi Therapeutics to Strengthen Gout Treatment Pipeline